305794-30-3

Upstream product

• 632-46-2 2,6-dimethylbenzoic acid 
• 305794-44-9 (4-bromo-phenyl)-(4'-methyl-[1,4']bipiperidinyl-4-yl)-methanone 
• 21900-37-8 2,6-dimethylbenzoyl chloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 126501-71-1 1-(2,2,2-trifluoroacetyl)piperidine-4-carbonyl chloride 
• 126501-70-0 1-(2,2,2-trifluoroacetyl)piperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 
• 305794-42-7 4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]-1'-(tert-butoxycarbonyl)-4'-cyano-1,4'-bipiperidine 

Downstream Products

• 1025813-61-9 (2,6-dimethyl-phenyl)-[4'-methyl-4-(4-methylsulfanyl-benzoyl)-[1,4']bipiperidinyl-1'-yl]-methanone 
• 438208-16-3 (2,6-dimethyl-phenyl)-[4'-methyl-4-(4-methylsulfanyl-benzyl)-[1,4']bipiperidinyl-1'-yl]-methanone 
• 305794-31-4 {4-[(4-bromo-phenyl)-hydroxy-methyl]-4'-methyl-[1,4']bipiperidinyl-1'-yl}-(2,6-dimethyl-phenyl)-methanone 

Relevant academic research and scientific papers

PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

Pharmaceutical compositions for the treatment of HIV are provided comprising compounds of formula (II) or a pharmaceutically acceptable salt or isomer thereof, in combination with specified antiviral agents.

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3 -pyridinyl)carbonyl]-4′-methyl-1,4′-bipipefidine N-oxide 1 (SCH 351125) as an orally bioavailable human CCR5 antagonist for the treatment of HIV-1 infec